Back to the future for multiple sclerosis therapy: focus on current and emerging disease-modifying therapeutic strategies

Immunotherapy
J Ludovic Croxford, Takashi Yamamura

Abstract

The last decade has seen numerous advances in the treatment of multiple sclerosis with six immunotherapeutic agents licensed for use. Although these therapeutic agents have powerful effects upon the inflammatory phase of disease, they have limitations in treating the progression of disability and in their safety profile. This review focuses on our current understanding of first- and second-line treatments for multiple sclerosis, including combination therapies, and also discusses the most promising novel therapeutic strategies on the horizon. Such agents include orally administered immunosuppressive drugs, monoclonal antibodies, antigen-specific tolerance, and neural protection and repair strategies. The challenge ahead lies in the delivery of potent drugs to inhibit inflammation and neurodegeneration while limiting side effects. Further elucidation of the pathophysiology of disease may provide new clinical targets and disease-relevant biomarkers that, in combination with proteomics, may help personalize treatment to individual patients.

References

Oct 26, 1991·Lancet·P L YudkinC Milanese
Aug 15, 1991·The New England Journal of Medicine·M K Sharief, R Hentges
Nov 1, 1991·Journal of Neuroimmunology·Y Kuroda, Y Shimamoto
Apr 1, 1991·Journal of Neuroimmunology·D MaimoneA T Reder
Mar 1, 1988·American Journal of Medical Genetics·A D SadovnickR H Ward
Aug 1, 1971·European Journal of Immunology·D TeitelbaumM Sela
Mar 1, 1993·Annals of Neurology·A D SadovnickT J Murray
May 8, 1997·Biochemical and Biophysical Research Communications·M VandermeerenJ Geysen
Oct 6, 1997·Proceedings of the National Academy of Sciences of the United States of America·R AharoniR Arnon
Jan 29, 1998·The New England Journal of Medicine·S G Waxman
Feb 29, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·J L CroxfordD Baker
Jun 22, 2000·Proceedings of the National Academy of Sciences of the United States of America·O NeuhausR Hohlfeld
May 24, 2001·Current Opinion in Neurology·C L KarpL Nagelkerken
Jun 13, 2001·Neurology·UNKNOWN Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group

❮ Previous
Next ❯

Citations

Sep 22, 2010·Photochemistry and Photobiology·Ann JohanssonHerbert Stepp
May 1, 2009·Immunotherapy·Thomas G Forsthuber, Paolo Muraro
Jan 20, 2016·Neurodegenerative Disease Management·Eva Costa ArpínManuela Lema Bouzas

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Annals of Indian Academy of Neurology
Daniel M Harrison, Peter A Calabresi
Recent Patents on Inflammation & Allergy Drug Discovery
Abbas Mirshafiey
Recent Patents on Inflammation & Allergy Drug Discovery
Farhad Jadidi-Niaragh, Abbas Mirshafiey
Bone Marrow Transplantation
G D Roodman
© 2021 Meta ULC. All rights reserved